バレット食道患者における高用量PPI+アスピリンで予後改善:factorialデザインの第Ⅲ相ランダム化比較試験AspECT【Lancet】

Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial.

Lancet 2018年7月26日オンライン版

BACKGROUND:Oesophageal adenocarcinoma is the sixth most common cause of cancer death worldwide and Barrett’s oesophagus is the biggest risk factor. We aimed to evaluate the efficacy of high-dose esomeprazole proton-pump inhibitor (PPI) and aspirin for improving outcomes in patients with Barrett’s oesophagus.

 

 

 

コメント

Leave a comment

Your email address will not be published.


*